DNASE1L3 Antibody

What is DNASE1L3 and what is its fundamental role in the immune system?

DNASE1L3 is one of the main enzymes responsible for extracellular DNase activity, alongside DNASE1. It specifically facilitates digestion of membrane- and/or protein-associated DNA, including intact chromatin. This specialized function distinguishes it from other DNases and makes it particularly important for processing cell-free DNA (cfDNA) .

DNASE1L3's critical immune function becomes evident when examining patients with DNASE1L3 deficiency. These individuals develop abnormalities in the length and distribution of cfDNA, as well as higher fractions of cfDNA in microparticles. This accumulation of inadequately processed DNA contributes to autoimmunity, particularly the development of anti-dsDNA antibodies, which are highly specific for lupus .

The importance of DNASE1L3 is further underscored by the fact that rare biallelic null mutations in the DNASE1L3 gene cause a monogenic form of SLE with childhood onset, demonstrating that this enzyme serves as a critical checkpoint in preventing autoimmunity against DNA-containing antigens .

What is the prevalence of anti-DNASE1L3 antibodies in SLE patients?

Multiple studies have consistently identified anti-DNASE1L3 antibodies in approximately one-third of patients with sporadic SLE. According to research published in the Journal of Experimental Medicine, antibody reactivity to DNASE1L3 was significantly increased in SLE patients compared to healthy controls (p < 0.001) .

Using a cutoff of two standard deviations above the mean anti-DNASE1L3 antibody level in healthy sera, researchers found that 30% (48/158) of SLE patients versus only 1.6% (1/62) of healthy controls were positive for anti-DNASE1L3 antibodies (p < 0.0001) . This prevalence appears consistent across different cohorts studied.

The prevalence is notably higher in patients with lupus nephritis, with studies showing that 43% (17/40) of evaluated patients with renal SLE demonstrated anti-DNASE1L3 antibody levels above the threshold . In contrast, only 18% (3/17) of plasma samples from non-renal SLE patients tested positive for these antibodies .

What clinical features are associated with anti-DNASE1L3 antibodies in SLE?

Anti-DNASE1L3 antibodies are associated with several distinct clinical and laboratory features in SLE patients. These include:

• Increased disease activity: Patients with anti-DNASE1L3 antibodies show significantly higher disease activity as measured by SELENA-SLEDAI scores [median (IQR): 3.4 (0-12) vs. 1.8 (0-12), p = 0.002] .

• Hematological abnormalities: Anemia is more common in anti-DNASE1L3 positive patients .

• Renal involvement: These antibodies are significantly associated with proteinuria and lupus nephritis .

• Complement abnormalities: Low complement levels are more frequently observed in anti-DNASE1L3 positive patients [31.2% (15/48) vs. 6.4% (7/110), p < 0.0001] .

• Cutaneous manifestations: Livedo reticularis is more common in anti-DNASE1L3 positive patients .

• Treatment intensity: At the time of assessment, anti-DNASE1L3 positive patients were more likely to be treated with prednisone [OR (95% CI) 2.6 (1.23-5.42)] and cytotoxic drugs [OR (95% CI) 4.6 (2.16-9.89)] independently of disease activity .

• Coexisting autoantibodies: Anti-DNASE1L3 antibodies are significantly associated with a broad range of autoantibodies, including anti-dsDNA, anti-cardiolipin, lupus anticoagulant, anti-β2-glycoprotein I, and anti-Ro52 antibodies .

How do genetic DNASE1L3 deficiency and antibody-mediated DNASE1L3 impairment compare?

Both genetic DNASE1L3 deficiency and antibody-mediated DNASE1L3 impairment lead to reduced DNASE1L3 activity, but they differ in several important aspects:

Genetic DNASE1L3 deficiency:

• Caused by biallelic null mutations in the DNASE1L3 gene

• Results in complete absence or severely reduced enzymatic activity

• Associated with childhood-onset SLE

• Represents a monogenic form of lupus

• Extremely rare in the population

Antibody-mediated DNASE1L3 impairment:

• Caused by autoantibodies that bind to and neutralize DNASE1L3

• Results in partial reduction of enzymatic activity

• Associated with adult-onset SLE, particularly with nephritis

• Represents a common non-genetic mechanism in sporadic SLE

• Present in approximately 30-43% of SLE patients

Despite these differences, both mechanisms lead to similar downstream effects, including abnormal cfDNA accumulation, particularly in microparticles, and the development of anti-dsDNA antibodies. This suggests a common pathogenic pathway whereby reduced DNASE1L3 activity, regardless of the cause, promotes autoimmunity against DNA-containing antigens .

What is the relationship between anti-DNASE1L3 antibodies and anti-dsDNA antibodies?

The relationship between anti-DNASE1L3 antibodies and anti-dsDNA antibodies is complex and multifaceted. Research has revealed several important connections:

• Coexistence: Anti-DNASE1L3 antibodies strongly associate with anti-dsDNA antibodies in SLE patients. Among anti-DNASE1L3 positive patients, 52.1% (25/48) had elevated anti-dsDNA compared to only 12.7% (14/110) of anti-DNASE1L3 negative patients (p < 0.0001) .

• Mechanistic link: DNASE1L3 deficiency promotes the formation of anti-dsDNA antibodies. When DNASE1L3 activity is reduced (either through genetic deficiency or neutralizing antibodies), there is impaired clearance of cell-free DNA, particularly DNA in microparticles, which can serve as immunogenic stimuli for anti-dsDNA antibody production .

• Cross-reactivity: A subset of anti-DNASE1L3 antibodies also directly cross-reacts with dsDNA. Through analysis of SLE serum and patient-derived monoclonal antibodies, researchers discovered that some anti-DNASE1L3 antibodies possess dual reactivity to both DNASE1L3 and dsDNA .

• Affinity maturation: These dual-reactive antibodies are highly mutated and can originate from both autoreactive and non-autoreactive precursors. Based on binding efficiency studies of mutated and germline-reverted monoclonal antibodies, the data suggest that DNASE1L3 is the primary target of these antibodies, with dsDNA being the cross-reactive antigen .

• Synergistic effect: The combination of anti-DNASE1L3 and anti-dsDNA positivity has an additive effect on clinical and transcriptional markers related to SLE disease activity, beyond what is observed with either antibody alone .

This complex relationship suggests that anti-DNASE1L3 antibodies may both facilitate anti-dsDNA antibody development (through reduced DNASE1L3 activity) and directly contribute to anti-dsDNA reactivity (through cross-reactivity), representing a significant amplification mechanism in SLE pathogenesis.

How does neutralization of DNASE1L3 contribute to SLE pathogenesis?

Neutralization of DNASE1L3 contributes to SLE pathogenesis through multiple interconnected mechanisms:

• Impaired cfDNA clearance: DNASE1L3 is responsible for digesting membrane- and protein-associated DNA, including intact chromatin. Neutralization of this enzyme leads to accumulation of cfDNA, particularly in microparticles .

• Exposure of immunogenic DNA: The accumulated cfDNA represents a source of self-antigen that can trigger and sustain autoimmune responses. DNASE1L3-sensitive antigens include DNA-associated proteins such as HMGB1, which can enhance the immunogenicity of DNA complexes .

• Type I interferon activation: Undigested DNA can activate nucleic acid sensors, triggering type I interferon production. Indeed, anti-DNASE1L3 antibodies associate with elevated interferon and myeloid/neutrophil gene signatures in SLE patients .

• Promotion of anti-dsDNA responses: The accumulation of DNA and DNA-protein complexes facilitates the development of anti-dsDNA autoantibodies, which are pathogenic in SLE and particularly associated with lupus nephritis .

• Vicious cycle amplification: Anti-DNASE1L3 antibodies reduce DNASE1L3 activity, leading to DNA accumulation, which promotes anti-dsDNA antibody development. Since some anti-DNASE1L3 antibodies cross-react with dsDNA, this creates a self-perpetuating cycle that amplifies autoimmunity .

• Enhanced neutrophil activation: Patients with anti-DNASE1L3 antibodies show elevated neutrophil counts and myeloid activation signatures, suggesting these antibodies may influence neutrophil biology, potentially including neutrophil extracellular trap (NET) formation, which is another source of immunogenic DNA .

Principal component analysis has shown that anti-DNASE1L3 antibodies identify a subset of SLE patients with higher disease activity, neutrophil count, and interferon/myeloid activation, which is also characterized by positivity for anti-dsDNA antibodies . This integrated view suggests that neutralization of DNASE1L3 sits at a crucial nexus in lupus pathogenesis.

What are the molecular characteristics of anti-DNASE1L3 antibodies?

Anti-DNASE1L3 antibodies display several distinctive molecular characteristics:

• Specificity: These antibodies show specific binding to DNASE1L3 with minimal cross-reactivity to the related enzyme DNASE1, as demonstrated by competition assays. Plasma from SLE patients with high anti-DNASE1L3 titers showed that IgG binding was competed out by DNASE1L3, but not by DNASE1 .

• V_H4-34 usage: A remarkable 40-80% of anti-DNASE1L3 antibodies in SLE serum contain the 9G4 idiotype, which is encoded by the autoreactive heavy-chain gene segment V_H4-34 . This gene segment is known to be inherently autoreactive and is enriched in antibodies against other SLE-relevant autoantigens.

• Somatic hypermutation: Analysis of patient-derived monoclonal antibodies revealed that anti-DNASE1L3 antibodies are highly mutated, indicating they have undergone affinity maturation in an antigen-driven process .

• Dual specificity: A subset of anti-DNASE1L3 antibodies also binds to dsDNA with high efficiency. These dual-reactive antibodies appear to have DNASE1L3 as their primary target with dsDNA as the cross-reactive antigen .

• Functional neutralization: Anti-DNASE1L3 antibodies possess neutralizing activity against DNASE1L3 enzymatic function. The levels of anti-DNASE1L3 antibodies strongly correlate with reduced plasma activity of DNASE1L3, and positive anti-DNASE1L3 binding in ELISA reliably identifies patients with DNASE1L3 activity below threshold levels .

• IgG isotype: The antibodies have undergone class switching to IgG and are derived from memory B cells, indicating a mature, established immune response rather than transient autoimmunity .

How do anti-DNASE1L3 antibodies influence cell-free DNA profiles in SLE patients?

Anti-DNASE1L3 antibodies significantly alter cell-free DNA (cfDNA) profiles in SLE patients through their neutralizing effect on DNASE1L3 enzymatic activity. These alterations manifest in several ways:

• Altered cfDNA length distribution: DNASE1L3 deficiency, whether genetic or antibody-mediated, leads to abnormalities in the length and distribution of cfDNA. Since DNASE1L3 is responsible for processing DNA fragments, its inhibition results in the persistence of longer cfDNA fragments .

• Increased microparticle-associated cfDNA: A particularly important consequence is the higher fraction of cfDNA found in microparticles. DNASE1L3 specifically facilitates digestion of membrane-associated DNA, and when its activity is reduced, DNA remains bound to microparticles rather than being released and degraded .

• Accumulation of DNA-protein complexes: DNASE1L3-sensitive antigens include DNA-associated proteins such as HMGB1. The neutralization of DNASE1L3 leads to accumulation of these DNA-protein complexes, which can be highly immunogenic .

• Enhanced generation of immunostimulatory DNA: The altered cfDNA profiles resulting from DNASE1L3 inhibition create a source of immunostimulatory DNA that can activate nucleic acid sensors and trigger type I interferon production, contributing to the interferon signature characteristic of SLE .

• Correlation with disease severity: Importantly, these alterations in cfDNA profiles correlate with disease severity. Autoantibodies to DNASE1L3-sensitive antigens on microparticles were prevalent in SLE nephritis patients and correlated with the accumulation of cfDNA in microparticles and with disease severity .

The impact of anti-DNASE1L3 antibodies on cfDNA profiles represents a mechanistic link between these autoantibodies and SLE pathogenesis, as the altered DNA landscapes serve as both drivers and sustaining factors for autoimmunity.

What are the transcriptomic signatures associated with anti-DNASE1L3 antibodies in SLE?

Anti-DNASE1L3 antibodies are associated with distinct transcriptomic signatures in SLE patients, reflecting their impact on immune pathways:

• Interferon signature: Patients with anti-DNASE1L3 antibodies exhibit a prominent interferon signature, characterized by upregulation of interferon-stimulated genes. This is consistent with the role of DNASE1L3 in processing DNA that might otherwise trigger nucleic acid sensors and type I interferon production .

• Myeloid/neutrophil signature: A notable myeloid/neutrophil gene expression signature is also associated with anti-DNASE1L3 antibodies. This includes elevation of blood transcription modules (BTMs) M1.2, M3.4, M5.12, M5.15, and M7.16, which are related to myeloid cell and neutrophil function .

• Correlation with neutrophil count: Principal component analysis showed that anti-DNASE1L3 antibodies identify a subset of SLE patients with higher neutrophil count along with the interferon/myeloid activation signature, suggesting a link between these antibodies and neutrophil biology .

• Synergistic effect with anti-dsDNA: The transcriptomic signatures associated with disease activity were most prominent in patients positive for both anti-DNASE1L3 and anti-dsDNA antibodies, compared to patients positive for either antibody alone. This suggests a synergistic effect of these autoantibodies on immune activation .

• Molecular stratification: The transcriptomic analysis revealed that anti-DNASE1L3 antibodies identify a molecularly distinct subset of SLE patients. Principal component analysis projection of disease activity and blood transcription modules showed that anti-DNASE1L3 antibody positivity delineates a more homogeneous group of patients with higher disease activity and immune activation, compared to the heterogeneous distribution of anti-DNASE1L3 negative patients, regardless of their anti-dsDNA status .

These transcriptomic signatures provide insight into the molecular mechanisms underlying the association between anti-DNASE1L3 antibodies and SLE disease severity, highlighting the role of these antibodies in promoting immune pathways activated by immunogenic self-DNA.

How can DNASE1L3 enzymatic activity be measured in research settings?

Researchers have developed several methodological approaches to measure DNASE1L3 enzymatic activity:

• Nuclease activity against chromatin in intact nuclei: This assay measures the ability of plasma samples to digest DNA in intact nuclei. The advantage of this approach is its specificity for DNASE1L3, as this enzyme has a unique ability to digest membrane- and protein-associated DNA, including intact chromatin. In this assay:

  • Nuclei stained with a DNA dye are incubated with diluted plasma samples

  • The loss of nuclear DNA signal is monitored by flow cytometry

  • DNASE1L3-deficient plasma fails to digest nuclear DNA at dilutions where normal plasma is effective

  • This assay can detect partial reductions in DNASE1L3 activity, such as in heterozygous carriers of hypomorphic variants (e.g., R206C)

• Relative DNASE1L3 activity calculation: To standardize measurements across samples:

  • The 50% inhibitory concentration (IC50) value for pooled healthy control plasma is set at 100%

  • The value for DNASE1L3-deficient patient plasma is set at 0%

  • Any activity below two standard deviations of the control (81%) is considered reduced

  • This approach allows for quantitative comparisons between samples

• Digestion of microparticle-associated DNA: Since DNASE1L3 specifically targets DNA associated with microparticles:

  • Microparticles are isolated from plasma or cell culture

  • These are treated with plasma samples or purified DNASE1L3

  • The amount of DNA released or remaining on microparticles is quantified

  • This assay specifically measures DNASE1L3's unique function

These methodological approaches allow researchers to assess DNASE1L3 activity in clinical samples and to investigate the functional consequences of genetic variants or neutralizing antibodies on DNASE1L3 function.

What techniques are used to detect and quantify anti-DNASE1L3 antibodies?

Several techniques have been developed and validated for the detection and quantification of anti-DNASE1L3 antibodies in research and clinical settings:

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • Purified DNASE1L3 protein is immobilized on plates

  • Patient plasma or serum is incubated at appropriate dilutions

  • Bound antibodies are detected using secondary antibodies against human IgG

  • A threshold is typically established as the mean optical density (OD) plus two standard deviations of healthy controls

  • This technique identified 43% of renal SLE patients as positive for anti-DNASE1L3 antibodies

• Competition assays:

  • To confirm specificity, plasma samples are pre-incubated with soluble DNASE1L3 or control proteins (e.g., DNASE1)

  • The mixture is then tested for binding to immobilized DNASE1L3 by ELISA

  • Specific anti-DNASE1L3 antibodies show reduced binding after pre-incubation with DNASE1L3 but not with control proteins

  • This approach helps distinguish specific antibodies from potential cross-reactive antibodies

• Immunoprecipitation:

  • Patient antibodies are used to immunoprecipitate DNASE1L3 from solution

  • The precipitated material is analyzed by Western blot or mass spectrometry

  • This technique can confirm the specificity of the antibody-antigen interaction

• Functional inhibition assays:

  • Patient IgG is purified and tested for its ability to inhibit DNASE1L3 enzymatic activity

  • This approach directly measures the neutralizing capacity of the antibodies

  • A strong correlation between anti-DNASE1L3 antibody levels in ELISA and reduced DNASE1L3 activity supports the functional relevance of these antibodies

• Idiotype-specific detection:

  • Since 40-80% of anti-DNASE1L3 antibodies contain the 9G4 idiotype (encoded by VH4-34), idiotype-specific reagents can be used

  • This approach can provide insights into the origin of these antibodies and potential connections to other autoantibodies

These techniques have been instrumental in establishing the prevalence and clinical associations of anti-DNASE1L3 antibodies in SLE and other autoimmune conditions.

How can researchers isolate and characterize monoclonal anti-DNASE1L3 antibodies?

The isolation and characterization of monoclonal anti-DNASE1L3 antibodies has provided crucial insights into their properties and pathogenic mechanisms. Researchers have employed several approaches:

These approaches have collectively advanced our understanding of anti-DNASE1L3 antibodies and their role in SLE pathogenesis.

How might testing for anti-DNASE1L3 antibodies improve SLE patient stratification?

Testing for anti-DNASE1L3 antibodies offers significant potential for improving SLE patient stratification, which could enhance both clinical management and research outcomes:

• Identification of a severe disease subset: Anti-DNASE1L3 antibodies identify a subset of SLE patients with higher disease activity as measured by SELENA-SLEDAI scores [median (IQR): 3.4 (0-12) vs. 1.8 (0-12), p = 0.002] . This stratification could help identify patients requiring more aggressive therapeutic approaches.

• Prediction of renal involvement: Anti-DNASE1L3 antibodies are significantly associated with lupus nephritis, with 43% of renal SLE patients positive for these antibodies compared to only 18% of non-renal SLE patients . Testing could help identify patients at higher risk for kidney involvement who might benefit from closer monitoring.

• Molecular classification: Principal component analysis has shown that anti-DNASE1L3 antibody positivity identifies a molecularly distinct subset of SLE patients characterized by higher neutrophil count and interferon/myeloid activation. This molecular stratification could be valuable for targeted therapeutic approaches .

• Complement to anti-dsDNA testing: The combination of anti-DNASE1L3 and anti-dsDNA positivity has an additive effect on clinical and transcriptional markers related to SLE disease activity. Testing for both antibodies might provide more comprehensive risk assessment than either alone .

• Treatment intensity guidance: At the time of assessment, anti-DNASE1L3 positive patients were more likely to be treated with prednisone [OR (95% CI) 2.6 (1.23-5.42)] and cytotoxic drugs [OR (95% CI) 4.6 (2.16-9.89)] independently of disease activity . This suggests that clinicians may already recognize the severity of disease in these patients, and formal testing could further standardize this approach.

• Mechanistic stratification: Testing for anti-DNASE1L3 antibodies provides insight into disease mechanisms (impaired DNA clearance, especially microparticle-associated DNA), which could help with selecting targeted therapies in the future .

Anti-DNASE1L3 antibody testing represents a promising biomarker that could enhance current approaches to SLE patient stratification, potentially leading to more personalized treatment strategies and improved outcomes.

What are the potential therapeutic implications of understanding anti-DNASE1L3 antibodies in SLE?

Understanding anti-DNASE1L3 antibodies in SLE opens several promising therapeutic avenues that could address specific pathogenic mechanisms:

• DNASE1L3 enzyme replacement therapy: Since a key consequence of anti-DNASE1L3 antibodies is reduced DNASE1L3 activity, administration of recombinant DNASE1L3 might help restore normal DNA processing. This approach would be analogous to DNase I (dornase alfa) therapy used in cystic fibrosis .

• Engineered DNASE1L3 variants: Development of DNASE1L3 variants that retain enzymatic activity but are resistant to neutralization by autoantibodies could provide a more effective replacement therapy for patients with anti-DNASE1L3 antibodies.

• B cell targeted therapies: Given that anti-DNASE1L3 antibodies are produced by autoreactive B cells (particularly those expressing VH4-34), therapies targeting these B cell populations might be effective. Existing therapies such as rituximab (anti-CD20) or belimumab (anti-BAFF) could be particularly beneficial in patients with anti-DNASE1L3 antibodies .

• Specific immunoadsorption: Development of columns containing immobilized DNASE1L3 could allow specific removal of anti-DNASE1L3 antibodies from the circulation of SLE patients, potentially breaking the cycle of enzyme inhibition and autoimmunity.

• Targeting microparticle clearance: Since anti-DNASE1L3 antibodies lead to accumulation of DNA in microparticles, therapies enhancing the clearance of these microparticles might reduce the burden of immunostimulatory DNA .

• Interferon pathway inhibition: The strong association between anti-DNASE1L3 antibodies and interferon signatures suggests that patients with these antibodies might particularly benefit from therapies targeting the type I interferon pathway, such as anifrolumab (anti-IFNAR) .

• Neutrophil-targeted approaches: The association between anti-DNASE1L3 antibodies and neutrophil/myeloid signatures suggests that therapies aimed at reducing neutrophil activation or NETosis might be beneficial in this patient subset .

These therapeutic implications highlight how understanding the mechanisms of anti-DNASE1L3 antibodies can inform more targeted and personalized approaches to SLE treatment, potentially improving outcomes in this heterogeneous disease.

What additional research is needed to better understand the role of anti-DNASE1L3 antibodies in autoimmunity?

Despite significant advances in our understanding of anti-DNASE1L3 antibodies, several important questions remain that warrant further research:

• Longitudinal studies: Most current data on anti-DNASE1L3 antibodies comes from cross-sectional studies. Longitudinal studies are needed to determine:

  • Whether these antibodies precede clinical disease

  • If antibody levels fluctuate with disease activity

  • Whether they predict disease flares or response to therapy

  • If they appear before or after anti-dsDNA antibodies

• Expanded clinical associations: Further research should examine associations between anti-DNASE1L3 antibodies and:

  • Specific organ manifestations beyond nephritis

  • Response to different therapeutic regimens

  • Long-term outcomes and prognosis

  • Comorbidities such as cardiovascular disease

• Mechanistic investigations: Additional studies are needed to elucidate:

  • The precise epitopes recognized by anti-DNASE1L3 antibodies

  • Whether epitope specificity correlates with clinical features

  • The mechanisms of B cell tolerance breakdown leading to anti-DNASE1L3 antibody production

  • How anti-DNASE1L3 antibodies affect neutrophil function and potentially NETosis

• Genetic associations: Research should explore:

  • Whether genetic variants in DNASE1L3 or related pathways influence susceptibility to anti-DNASE1L3 antibody development

  • If rare variants in DNASE1L3 (like R206C) interact with anti-DNASE1L3 antibodies to enhance disease risk

• Therapeutic studies: Clinical trials should assess:

  • The efficacy of existing therapies specifically in anti-DNASE1L3 positive patients

  • Novel approaches such as DNASE1L3 enzyme replacement

  • Whether anti-DNASE1L3 antibody levels could serve as biomarkers of treatment response

• Relevance to other autoimmune diseases: Exploration of anti-DNASE1L3 antibodies in:

  • Other systemic autoimmune diseases beyond SLE

  • Conditions with interferon signatures similar to SLE

  • Organ-specific autoimmune disorders

• Development of standardized assays: To facilitate research and potential clinical applications:

  • Standardized methods for measuring anti-DNASE1L3 antibodies

  • Validated assays for assessing DNASE1L3 activity

  • Consensus on thresholds for positivity

Addressing these research gaps would significantly advance our understanding of anti-DNASE1L3 antibodies and potentially lead to improved diagnostic and therapeutic approaches for SLE and related disorders.